Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood proteins may predict who beats esophageal cancer with chemoradiation

NCT ID NCT00911092

Knowledge-focused Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are studying whether protein patterns in the blood can predict which people with esophageal cancer will respond completely to combined chemotherapy and radiation. The trial enrolls about 50 adults with invasive esophageal cancer who receive standard radiochemotherapy. Blood samples are taken before treatment and at set times during and after therapy to analyze proteins. The goal is to link early protein changes to treatment response and one-year outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the protein patterns predict who responds to radiochemotherapy, doctors could tailor treatment earlier and spare non-responders from ineffective therapy.
What could go wrong
This small observational study may not find reliable protein markers, and results might not apply to all esophageal cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

50 people

The number who actually took part.

Start date

Oct 2007

Finished

Dec 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a), histologically proven * Treated by exclusive concomitant radiochemotherapy * Written informed consent Exclusion Criteria: * Presence of a second uncontrolled cancer * Metastatic carcinoma * Metastatic disease, except cervical lymphnodes... (M1a) * In situ carcinoma * Eso-gastric junction cancer (Siewert II ou III) * Inclusion in a clinical trial with an experimental drug during the study and until 15 weeks after the end of radiotherapy)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma of esophagus esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal cancer

Contacts and locations

Locations

  • CHU - Hopital Charles Nicolle

    Rouen, 76031, France

  • Centre Eugène Marquis

    Rennes, 35042, France

  • Centre François BACLESSE

    Caen, 14046, France

  • Centre Hospitalier Universitaire

    Brest, 29200, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Centre Paul Papin

    Angers, 49933, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.